View in EDS

The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

Saved in:
Bibliographic Details
Title: The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels
Authors: Park, Hyohun1,2, Hasegawa, Goji2 goji@koto.kpu-m.ac.jp, Shima, Toshihide1, Fukui, Michiaki2, Nakamura, Naoto2, Yamaguchi, Kanji3, Mitsuyoshi, Hironori3, Minami, Masahito3, Yasui, Kohichiroh3, Itoh, Yoshito3, Yoshikawa, Toshikazu3, Kitawaki, Jo4, Ohta, Mitsumiro5, Obayashi, Hiroshi6, Okanoue, Takeshi1,3
Source: Clinica Chimica Acta. Nov2010, Vol. 411 Issue 21/22, p1735-1740. 6p.
Subjects: Fatty liver, Ezetimibe, Lipid metabolism, Unsaturated fatty acids, Lecithin, Low density lipoproteins, Insulin resistance, Metabolic syndrome
Abstract: Abstract: Background: The aim of this study was to investigate the relationship between fatty acid composition of plasma cholesteryl esters (CEs) and estimated desaturase activity and the development and progression of nonalcoholic fatty liver disease (NAFLD). The study also assessed the effect of ezetimibe on CE levels. Methods: Plasma CEs fatty acid composition was analyzed in 3 groups: patients with a NAFLD activity score (NAS) ≤4 (n=31) or NAS ≥5 (n=32) and normal controls (n=25). The estimated desaturase activities were calculated using ratios of 16:1n−7/16:0 (D9-16D), 18:1n−9/18:0 (D9-18D), 18:3n−6/18:2n−6 (D6D) and 20:4n−6/20:3n−6 (D5D). Results: Compared with controls, the levels of palmitate, palmitoleate, γ-linoleate, D9-16D and D6D were significantly increased, whereas levels of linoleate and D5D were significantly decreased. Patients with NAS ≥5 had significantly higher palmitate levels than patients with NAS ≤4. The levels of these fatty acids, especially palmitate and palmitoleate, correlated with NAFLD-related lipid, metabolic, and inflammatory parameters. Long-term therapy with ezetimibe caused significant improvements in the levels of these fatty acids, estimated desaturase activity index and NAFLD-related parameters. Conclusions: Our results suggest that fatty acids and desaturase activity associate with the development and progression of NAFLD, and that ezetimibe may be a novel treatment for this disorder. [ABSTRACT FROM AUTHOR]
Copyright of Clinica Chimica Acta is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Abstract: Background: The aim of this study was to investigate the relationship between fatty acid composition of plasma cholesteryl esters (CEs) and estimated desaturase activity and the development and progression of nonalcoholic fatty liver disease (NAFLD). The study also assessed the effect of ezetimibe on CE levels. Methods: Plasma CEs fatty acid composition was analyzed in 3 groups: patients with a NAFLD activity score (NAS) ≤4 (n=31) or NAS ≥5 (n=32) and normal controls (n=25). The estimated desaturase activities were calculated using ratios of 16:1n−7/16:0 (D9-16D), 18:1n−9/18:0 (D9-18D), 18:3n−6/18:2n−6 (D6D) and 20:4n−6/20:3n−6 (D5D). Results: Compared with controls, the levels of palmitate, palmitoleate, γ-linoleate, D9-16D and D6D were significantly increased, whereas levels of linoleate and D5D were significantly decreased. Patients with NAS ≥5 had significantly higher palmitate levels than patients with NAS ≤4. The levels of these fatty acids, especially palmitate and palmitoleate, correlated with NAFLD-related lipid, metabolic, and inflammatory parameters. Long-term therapy with ezetimibe caused significant improvements in the levels of these fatty acids, estimated desaturase activity index and NAFLD-related parameters. Conclusions: Our results suggest that fatty acids and desaturase activity associate with the development and progression of NAFLD, and that ezetimibe may be a novel treatment for this disorder. [ABSTRACT FROM AUTHOR]
ISSN:00098981
DOI:10.1016/j.cca.2010.07.012